Physician profile
Michael A Elliott
NPI 1518986199
$34,398.92
in general payments reported to CMS, 2019-2025
12 companies · $5,475 in 2025
The $5,475 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $949 · 2020: $3,900 · 2021: $1,575 · 2022: $116 · 2023: $19K · 2024: $3,730 · 2025: $5,475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Consulting Fee: $1,925 · Travel and Lodging: $572 · Food and Beverage: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $14,682.49 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,150.00 |
| Consulting Fee | $1,925.00 |
| Travel and Lodging | $572.45 |
| Food and Beverage | $528.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amylyx Pharmaceuticals, INC. | $15,541.94 | 2023-2024 | Relyvrio |
| Tanabe Pharma America, INC. | $12,121.77 | 2023-2025 | Radicava Ors |
| Biogen, INC. | $6,371.08 | 2019-2023 | Spinraza |
| Argenx US, INC. | $129.09 | 2022-2024 | Vyvgart Hytrulo |
| Janssen Scientific Affairs, LLC | $125.00 | 2024 | Tremfya |
| Edw Pharma, INC. | $67.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.20 | 2024 | Ajovy |
| Abbvie INC. | $14.00 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Elliott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.